Figma Shares Indicated To Open $105/$110
Investing.com -- Shares of Hims & Hers Health, Inc. (NYSE: HIMS) climbed 30% following the announcement of a long-term collaboration with Novo Nordisk (NYSE:NVO) to enhance obesity care. The partnership aims to make obesity treatments more accessible and affordable for Americans through the Hims & Hers platform.
The collaboration introduces a bundled offering that includes Novo Nordisk’s popular weight loss drug Wegovy and a Hims & Hers membership, providing 24/7 care, clinical support, and nutrition guidance. Starting at $599 per month, the service is now available on the Hims & Hers platform, marking the first step in a broader roadmap to improve obesity care outcomes.
The companies’ joint efforts will leverage Novo Nordisk’s expertise in clinical medicine with Hims & Hers’ digital health platform to scale access to quality care. This initiative expands on Hims & Hers’ existing weight loss solutions, offering a comprehensive approach to health management with a variety of medications, kits, and care plans.
Andrew Dudum, CEO and founder of Hims & Hers, expressed enthusiasm about the partnership, highlighting the shared commitment to innovating healthcare delivery. Dave Moore, Executive Vice President of Novo Nordisk Inc., also underscored the goal of improving chronic disease outcomes more affordably through this collaboration.
The stock’s positive movement reflects investor optimism around the potential for Hims & Hers to broaden its service offerings and tap into the growing demand for accessible healthcare solutions.